Evidence map›Paper›PMID 36010561›Full record

ReviewCells2022

Cellular Therapies in Pediatric Liver Diseases.

Sunitha Vimalesvaran, Jessica Nulty, Anil Dhawan

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sunitha VimalesvaranPediatric Liver GI and Nutrition Center and Mowat Labs, Institute of Liver Studies, King's College London and King's College Hospital, London SE5 9RS, UK.
Jessica NultyPediatric Liver GI and Nutrition Center and Mowat Labs, Institute of Liver Studies, King's College London and King's College Hospital, London SE5 9RS, UK.
Anil DhawanPediatric Liver GI and Nutrition Center and Mowat Labs, Institute of Liver Studies, King's College London and King's College Hospital, London SE5 9RS, UK.
King's College Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver transplantation is the gold standard for the treatment of pediatric end-stage liver disease and liver based metabolic disorders. Although liver transplant is successful, its wider application is limited by shortage of donor organs, surgical complications, need for life long immunosuppressive medication and its associated complications. Cellular therapies such as hepatocytes and mesenchymal stromal cells (MSCs) are currently emerging as an attractive alternative to liver transplantation. The aim of this review is to present the existing world experience in hepatocyte and MSC transplantation and the potential for future effective applications of these modalities of treatment.

Indexed as

End Stage Liver DiseaseLiver DiseasesChildHepatocytesHumansSeverity of Illness Indexacute liver failurehepatocyte transplantationmesenchymal stromal cellpediatric liver transplantation

Identifiers

PMID36010561
PMCPMC9406752
OpenAlexW4290999090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.